The future, page-4

I share your hope but I am more cynical.

This funding comes at a true transitional point for Optiscan as it nears the launch of its first
imaging systems using Optiscan’s latest second generation technology platform.

"nears the launch" translates to unexpected delays mean that CellLIVE is not finished. It's still nearly there but not quite.

This platform is the outcome of more than 20 years R&D and $100m of investment...

I read: We have managed to turn $100 Mil into a $10 Mil company and we are proud of it.

They've been to the payday lenders and borrowed $500 Mil to be repaid out of their tax refund.

But I share your positive sentiment because I think that sales are just waiting on product being available. Pre-sales activity has been going on for some time now. The product will be wildly successful. I think the underwriters of the  share issue know this, and know the product is nearly finished. They know they just have to keep the company solvent for a few months.
I won't buy more but I'll hold.